Abbott spins off AbbVie (2013)
Abbott Laboratories split its branded pharmaceuticals business into a new company, AbbVie, which began trading January 2, 2013. AbbVie entered the S&P 500 the same day, alongside its former parent.
Abbott stayed in the S&P 500 while AbbVie joined the index at the split.
AbbVie has remained in the benchmark since, and the structure became a template for large pharmaceutical separations.
The pattern of a large-cap parent spinning off a business that immediately joins the S&P 500 matches the Corteva-Vylor transaction.
